Klotho Neurosciences, Inc.

Filed Apr 1, 2026

Accepted Apr 1, 2026, 5:09 PM ET

KLTOW

CIK 0001907223

View on SEC.gov Company Profile

AI Analysis

AI-generated analysis. Always verify with the original filing.

Klotho Neurosciences reported a wider operating and net loss in FY2025, reflecting continued investment in its pre-revenue pipeline and public company infrastructure, with cash burn accelerating as expected during development.

Key Takeaways

1Operating loss expanded to $7.1M from $5.5M due to higher R&D, G&A, and professional fees, consistent with pipeline advancement and post-merger public company costs.

2Net loss increased 71.6% year-over-year to $10.6M, driven by higher operating expenses, interest expense, and a settlement charge, partially offset by other income.

3Diluted EPS improved to -$0.22 from -$0.32, reflecting both the net loss increase and a larger share count following equity financing activities.

4Net cash used in operating activities nearly doubled to $5.9M, primarily due to rising operational expenses tied to expanding development efforts.

5The company remains pre-revenue and dependent on future equity or debt financing to fund operations, as highlighted in management’s liquidity commentary.

6Cash and working capital stood at $7.2M and $7.2M respectively as of December 31, 2025, providing near-term runway but subject to ongoing burn.

Operating Performance and Expense Drivers

Net Loss and Non-Operating Factors

Cash Flow and Liquidity Outlook

Net cash used in operating activities rose to $5.9 million in FY2025 from $2.9 million the previous year, nearly doubling as anticipated. Management attributes this acceleration to increased costs from expanding operations and ongoing public company requirements. Despite the rising burn, the company ended the year with $7.2 million in cash and positive net working capital of $7.2 million, providing short-term stability. However, with no revenue-generating products, Klotho remains reliant on external financing to sustain operations, a point reiterated in its forward-looking statements.

Key Financial Metrics

EPS

$-0.22

31.2%

Net Income

-$10.6M

-71.6%

Operating Income

-$7.1M

-29.0%